October 1, 2009 - Astellas Pharma Canada, Inc. and Theravance, Inc. announced today that Health Canada has approved VIBATIV™ (telavancin) for the treatment of adult patients with complicated skin and skin structure infections (cSSSI) caused by susceptible Gram-positive bacteria, including Staphylococcus aureus, both methicillin-resistant (MRSA) and methicillin-susceptible (MSSA) strains.
The details can be read here.
No comments:
Post a Comment